Bromfenac (Duract)-associated hepatic failure requiring liver transplantation
- PMID: 10445569
- DOI: 10.1111/j.1572-0241.1999.01321.x
Bromfenac (Duract)-associated hepatic failure requiring liver transplantation
Abstract
Bromfenac sodium (Duract) is a phenylacetic acid-derived nonsteroidal anti-inflammatory agent introduced in the United States in 1997 and withdrawn in 1998. We describe the first case of fulminant hepatic failure associated with this agent treated successfully with liver transplantation. Similarities to hepatotoxicity with related agents is discussed.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical